Tenaya Therapeutics Future Growth
Future criteria checks 5/6
Tenaya Therapeutics is forecast to grow earnings and revenue by 61.5% and 80.1% per annum respectively. EPS is expected to grow by 57.7% per annum. Return on equity is forecast to be -72.9% in 3 years.
Key information
61.5%
Earnings growth rate
57.7%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 80.1% |
| Future return on equity | -72.9% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Sep 18
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
Jun 04Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Dec 20Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely
Mar 07Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?
Dec 06Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment
Sep 06Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07
Aug 10Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely
Mar 03Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth
Nov 01Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms
Aug 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 26 | -121 | N/A | -127 | 5 |
| 12/31/2025 | 3 | -120 | N/A | -108 | 7 |
| 12/31/2024 | N/A | -114 | N/A | -103 | 7 |
| 9/30/2024 | N/A | -117 | -95 | -94 | N/A |
| 6/30/2024 | N/A | -121 | -99 | -98 | N/A |
| 3/31/2024 | N/A | -125 | -102 | -100 | N/A |
| 12/31/2023 | N/A | -124 | -103 | -102 | N/A |
| 9/30/2023 | N/A | -128 | -104 | -103 | N/A |
| 6/30/2023 | N/A | -129 | -112 | -107 | N/A |
| 3/31/2023 | N/A | -124 | -119 | -106 | N/A |
| 12/31/2022 | N/A | -124 | -125 | -104 | N/A |
| 9/30/2022 | N/A | -116 | -130 | -98 | N/A |
| 6/30/2022 | N/A | -104 | -121 | -87 | N/A |
| 3/31/2022 | N/A | -91 | -103 | -74 | N/A |
| 12/31/2021 | N/A | -73 | -86 | -61 | N/A |
| 9/30/2021 | N/A | -57 | -76 | -55 | N/A |
| 6/30/2021 | N/A | -49 | -64 | -48 | N/A |
| 3/31/2021 | N/A | -42 | -57 | -43 | N/A |
| 12/31/2020 | N/A | -38 | -45 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TNYA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: TNYA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TNYA is expected to become profitable in the next 3 years.
Revenue vs Market: TNYA's revenue (80.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: TNYA's revenue (80.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TNYA is forecast to be unprofitable in 3 years.